

Special Issue

Infectious Endocarditis: Diagnosis and Antimicrobial Therapy

Message from the Guest Editors

Infective endocarditis (IE) is still an infection with severe morbidity and mortality despite medical, surgical and therapeutic progress. IE affects the endocardial surfaces of the heart—usually of one or more cardiac valves; to a lesser degree the mural endocardium; or a septal defect. IE may lead to severe valvular insufficiency, intractable congestive heart failure, and myocardial abscesses. IE may produce a wide range of signs and symptoms, including infected and sterile emboli and a variety of immunological pathways. If its diagnosis is unduly delayed or treatment is inadequate, IE is inevitably fatal. For this Special Issue, we invite you to contribute original research articles, case reports, and review papers addressing: epidemiology, antibiotic prophylaxis and its effects; clinical aspects; diagnosis: imaging and microbiology; antimicrobial therapy; surgical treatment

Guest Editors

Dr. Carlo Pallotto

Dr. Lorenzo Roberto Suardi

Dr. Giuseppe Vittorio Luigi De Socio

Deadline for manuscript submissions

closed (30 June 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/131189

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)